Pharmacodynamics, pharmacokinetics, and safety of AM211: A novel and potent antagonist of the prostaglandin D2 receptor type 2

Journal of Clinical Pharmacology

Volumn 52, Issue 10, 2012, Pages 1482-1493

  Bain, G ^a   King, C D ^a   Brittain, J ^a   Hartung, J P ^a   Dearmond, I ^a   Stearns, B ^b   Truong, Y P ^b   Hutchinson, J H ^c   Evans, J F ^d   Holme, K ^a  

^a Amira Pharmaceuticals   (United States)

^b Current affiliation Inception Sciences Inc   (United States)

^c BrainCells Inc   (United States)

^d CELGENE CORPORATION   (United States)

Author keywords

AM211; CRTH2; DP2; pharmacodynamics; pharmacokinetics

Indexed keywords

[2' (3 BENZYL 1 ETHYLUREIDOMETHYL) 6 METHOXY 4' TRIFLUOROMETHYLBIPHENYL 3 YL] ACETIC ACID SODIUM SALT; AM 211; PLACEBO; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; CELL SHAPE; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; EOSINOPHIL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AREA UNDER CURVE; DOUBLE-BLIND METHOD; EOSINOPHILS; FEMALE; HUMANS; MALE; METHYLUREA COMPOUNDS; MIDDLE AGED; PHENYLACETATES; PROSTAGLANDIN D2; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; YOUNG ADULT;

EID: 84870409539     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011421912     Document Type: Article

References (33)

1. Lewis RA, Soter NA, Diamond PT, et al. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol. 1982 ; 129: 1627-1631
2. Murray JJ, Tonnel AB, Brash AR, et al. Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med. 1986 ; 315: 800-804
3. Naclerio RM, Meier HL, Kagey-Sobotka A, et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis. 1983 ; 128: 597-602
4. Charlesworth EN, Kagey-Sobotka A, Schleimer RP, Norman PS, Lichtenstein LM.. Prednisone inhibits the appearance of inflammatory mediators and the influx of eosinophils and basophils associated with the cutaneous late-phase response to allergen. J Immunol. 1991 ; 146: 671-676
5. Hardy CC, Robinson C, Tattersfield AE, Holgate ST.. The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men. N Engl J Med. 1984 ; 311: 209-213
6. Emery DL, Djokic TD, Graf PD, Nadel JA.. Prostaglandin D2 causes accumulation of eosinophils in the lumen of the dog trachea. J Appl Physiol. 1989 ; 67: 959-962
7. Pettipher R.. The roles of the prostaglandin D2 receptors DP1 and CRTH2 in promoting allergic responses. Br J Pharmacol. 2008 ; 153 (suppl 1). S191 - S199
8. Arima M, Fukuda T.. Prostaglandin D2 receptors DP and CRTH2 in the pathogenesis of asthma. Curr Mol Med. 2008 ; 8: 365-375
9. Oguma T, Asano K, Ishizaka A.. Role of prostaglandin D2 and its receptors in the pathophysiology of asthma. Allergol Int. 2008 ; 57: 307-312
10. Philip G, van Adelsberg J, Loeys T, et al. Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. J Allergy Clin Immunol. 2009 ; 124: 942-948
11. Nagata K, Hirai H, Tanaka K, et al. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett. 1999 ; 459: 195-199
12. Nagata K, Tanaka K, Ogawa K, et al. Selective expression of a novel surface molecule by human Th2 cells in vivo. J Immunol. 1999 ; 162: 1278-1286
13. Gervais FG, Cruz RP, Chateauneuf A, et al. Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J Allergy Clin Immunol. 2001 ; 108: 982-988
14. Xue L, Gyles SL, Wettey FR, et al. Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol. 2005 ; 175: 6531-6536
15. Yoshimura-Uchiyama C, Iikura M, Yamaguchi M, et al. Differential modulation of human basophil functions through prostaglandin D2 receptors DP and chemoattractant receptor-homologous molecule expressed on Th2 cells/DP2. Clin Exp Allergy. 2004 ; 34: 1283-1290
16. Hirai H, Tanaka K, Yoshie O, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med. 2001 ; 193: 255-261
17. Gonzalo J, Qiu Y, Coyle A, Hodge M.. CRTH2(DP2) and not DP1 receptor mediate allergen induced mucus production and airway hyperresponsiveness. Am J Respir Crit Care Med. 2005 ; 163: A811
18. Satoh T, Moroi R, Aritake K, et al. Prostaglandin D2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. J Immunol. 2006 ; 177: 2621-2629
19. Takeshita K, Yamasaki T, Nagao K, et al. CRTH2 is a prominent effector in contact hypersensitivity-induced neutrophil inflammation. Int Immunol. 2004 ; 16: 947-959
20. Uller L, Mathiesen JM, Alenmyr L, et al. Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. Respir Res. 2007 ; 8: 16
21. Lukacs NW, Berlin AA, Franz-Bacon K, et al. CRTH2 antagonism significantly ameliorates airway hyperreactivity and downregulates inflammation-induced genes in a mouse model of airway inflammation. Am J Physiol Lung Cell Mol Physiol. 2008 ; 295: L767 - L779
22. Stebbins KJ, Broadhead AR, Correa LD, et al. Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation. Eur J Pharmacol. 2010 ; 638: 142-149
23. Gervais FG, Sawyer N, Stocco R, et al. Pharmacological characterization of MK-7246, a potent and selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells) antagonist. Mol Pharmacol. 2011 ; 79: 69-76
24. Oiwa M, Satoh T, Watanabe M, et al. CRTH2-dependent, STAT6-independent induction of cedar pollen dermatitis. Clin Exp Allergy. 2008 ; 38: 1357-1366
25. Stebbins KJ, Broadhead AR, Baccei CS, et al. Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lung. J Pharmacol Exp Ther. 2010 ; 332: 764-775
26. Sargent C, Stinson S, Schmidt J, et al. The effect of a selective CRTh2 antagonist on tobacco smoke (TS) induced airway inflammation and remodelling in the mouse. Proceedings of the British Pharmacological Society. Seventh James Black Conference ; London, United Kingdom ;..
27. Pettipher R, Hansel TT, Armer R.. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov. 2007 ; 6: 313-325
28. Bain G, Lorrain DS, Stebbins KJ, et al. Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation. J Pharmacol Exp Ther. 2011 ; 338: 290-301
29. Sabroe I, Hartnell A, Jopling LA, et al. Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways. J Immunol. 1999 ; 162: 2946-2955
30. Chevalier E, Stock J, Fisher T, et al. Cutting edge: chemoattractant receptor-homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and eosinophil recruitment. J Immunol. 2005 ; 175: 2056-2060
31. Cirri M, Mura P, Mora PC.. Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems. Int J Pharm. 2007 ; 340: 84-91
32. Bell S, Anderson L, Nugent C, et al. Safety, PK and PD of ARRY-502, a CRTh2 antagonist, in healthy subjects with a history of seasonal allergies. European Respiratory Society Annual Congress, Barcelona, Spain. 2010 ;:
33. Norman P.. DP2 receptor antagonists in development. Expert Opin Investig Drugs. 2010 ; 19: 947-961